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Chronic colitis is associated with increased risk for colo-
rectal cancer. CRHR2/Ucn2 has an inhibitory effect on
signaling of tumor growth and metastatic potential through
regulation of colonic inﬂammation, and may have a thera-
peutic and prognostic impact on colorectal cancer.
BACKGROUND & AIMS: Chronic inﬂammation promotes
development and progression of colorectal cancer (CRC). We
explored the distribution of the corticotropin-releasing-
hormone (CRH) family of receptors and ligands in CRC and
their contribution in tumor growth and oncogenic epithelial-to-
mesenchymal transition (EMT).
METHODS: The mRNA expression of CRH-family members was
analyzed in CRC (n ¼ 56) and control (n ¼ 46) samples, seven
CRC cell lines, and normal NCM460 cells. Immunohistochemical
detection of CRHR2 was performed in 20 CRC and ﬁve normal
tissues. Cell proliferation, migration, and invasion were
compared between urocortin-2 (Ucn2)-stimulated parental and
CRHR2-overexpressing (CRHR2þ) cells in the absence or
presence of interleukin-6 (IL-6). CRHR2/Ucn2-targeted effects
on tumor growth and EMT were validated in SW620-xenograft
mouse models.
RESULTS: CRC tissues and cell lines showed decreased mRNA
and protein CRHR2 expression compared with controls and
NCM460 cells, respectively. The opposite trend was shown for
Ucn2. CRHR2/Ucn2 signaling inhibited cell proliferation, migra-
tion, invasion, and colony formation in CRC-CRHR2þ cells. In vivo,
SW620-CRHR2þ xenografts showed decreased growth, reduced
expression of EMT-inducers, and elevated levels of EMT-
suppressors. IL-1b, IL-6, and IL-6R mRNAs were diminished in
CRC-CRHR2þ cells, while CRHR2/Ucn2 signaling inhibited IL-6-
mediated Stat3 activation, invasion, migration, and expression
of downstream targets acting as cell cycle– and EMT-inducers.
Expression of cell cycle– and EMT-suppressors was augmentedin IL-6/Ucn2-stimulated CRHR2þ cells. In patients, CRHR2mRNA
expression was inversely correlated with IL-6R and vimentin
levels andmetastasis occurrence, while positively associatedwith
E-cadherin expression and overall survival.
CONCLUSIONS: CRHR2 down-regulation in CRC supports
tumor expansion and spread through maintaining persistent
inﬂammation and constitutive Stat3 activation. CRHR2low
CRC phenotypes are associated with higher risk for dis-
tant metastases and poor clinical outcomes. (Cell Mol Gastro-
enterol Hepatol 2015;1:610–630; http://dx.doi.org/10.1016/
j.jcmgh.2015.08.001)
Keywords: Colorectal Cancer; Inﬂammation; Metastasis;
Neuropeptides.
hronic inﬂammation is a driving force for the growthCof many human malignancies. Inﬂammatory diseases
such as inﬂammatory bowel disease (IBD) are associated
November 2015 CRHR2 Inhibition Promotes CRC Metastasis 611with increased risk for colorectal cancer (CRC).1 The
corticotropin-releasing hormone (CRH) family of receptors,
CRHR1 and CRHR2 and their ligands CRH, urocortin-1
(Ucn1), -2, and -3 are well-characterized with an estab-
lished role in the regulation of intestinal inﬂammation.2
However, their net effects on CRC development and pro-
gression remain unclear, especially under conditions of
chronic inﬂammation.
Although CRH family members are best known as prin-
cipal neuroendocrine regulators of the stress response in the
central nervous system, they are also peripherally expressed
and act as autocrine or paracrine pro- or anti-inﬂammatory
factors in several diseases, including IBD.3,4 The distribu-
tion of these peptides and receptors has been well described
in the intestine;4,5 but current knowledge of their expression
in gastrointestinal tumors is limited. Expression of CRH-
family members has been documented for only a few can-
cers and reported to follow tissue-speciﬁc expression pat-
terns. CRHR2 is preferentially expressed in endocrine
tumors, whereas CRHR1 is predominant in tumors of the
nervous system.6 CRH and/or Ucn overexpression has been
reported in reproductive malignancies and breast cancer
tumors.7–9 Low or absent CRHR1 and CRHR2 expression was
found in exocrine ductal pancreatic carcinomas, prostate
cancer, and non-small cell lung cancer.6
In addition to expression discrepancies, the functional
role of the CRH-system in cancer remains controversial.
CRHR2 activation by CRH showed inhibition of apoptosis in
gynecologic cancers and induction of tumor cell prolifera-
tion, migration, and invasion.10,11 In contrast, CRHR1/CRH
promoted apoptosis in breast cancer and endometrial
adenocarcinoma, and Ucn and Ucn2 enhanced malignant cell
growth in the human stomach via CRHR2.12–14 In hepato-
cellular carcinoma, Ucn inhibited tumor growth via
thwarting angiogenesis, while neovascularization and pros-
tate cancer development are associated with CRHR2 down-
regulation.15,16 Different molecular mechanisms triggering
CRHR1- and CRHR2-driven effects on tumors might
contribute to these inconsistencies, but further clariﬁcation
is needed. In addition, endogenous ligands might complicate
tumorigenesis, favoring progression or suppression
depending on the cancer type and relative distribution of
CRHRs.
To our knowledge, it has not been clearly elucidated
whether CRH family members are differentially expressed
in CRC and/or impact CRC pathophysiology, especially in
response to colonic inﬂammation. Contrary to an initial
study showing lost CRHR2 expression in 10 CRC samples,6
a recent study reported elevated levels of CRHR2 and
Ucn3 in 30 CRC patient samples that were correlated with
decreased cell adhesion and enhanced cell motility.17
Thus, studies with larger cohorts are needed to elucidate
the functional role of CRH receptors and their peptides on
CRC. The present study was designed to 1) determine the
distribution of CRH-related components in CRC cell lines
and human tissues relative to their normal counterparts,
2) delineate the functional impact of any detected
expression differences in CRH molecules on tumor growth
and metastatic potential, and 3) explore the underlyingmolecular mechanisms associated with chronic inﬂam-
matory responses.
Materials and Methods
Cell Lines and Culture Conditions
Seven human CRC cell lines (SW480, SW620, DLD1,
SW403, HT29, HCT116, Caco2) and one immortalized hu-
man colonic epithelial cell line (NCM460) (all from Amer-
ican Type Culture Collection [ATCC], Manassas, VA) were
used in the study. The cell lines were cultured in the
following media: SW480, SW620, and DLD1 in RPMI 1640
(cat. no. 11875-093; Invitrogen, Grand Island, NY); SW403
in Ham’s F-12 medium (cat. no. 11765-054; Invitrogen);
HT29 and HCT116 in McCoy’s 5A (cat. no. 30-2007; ATCC);
CaCo2 in minimal essential medium (11095-080; Invi-
trogen), and NCM460 in M3:D (cat no. M3DEF; InCell Cor-
poration, San Antonio, TX). All media were supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS),
10 U/mL penicillin, and 100 mg/mL streptomycin (Gibco,
Carlsbad, CA). Cells were incubated at 37C with 5% CO2.
The CRHR2-transduced cells were cultured as above with 2
mg/mL of puromycin (Sigma-Aldrich, Natick, MA). The
institutional biosafety committee approved all procedures
involving human cells.
Human Samples for mRNA Analysis
Fifty-six CRC samples were obtained from surgical re-
sections from patients with CRC diagnosed with established
criteria (Table 1). The control group included samples from
disease-free donors and noninvolved colonic tissues obtained
from ulcerative colitis patients (n ¼ 46). Each tissue was
immediately snap frozen for RNA extraction as described
herein. The CRC tissue samples were provided by the
Department of Gastroenterology and Hepatology of Leiden
University Medical Center (LUMC) and were conﬁrmed by
histopathologic evaluation. The samples were obtained ac-
cording to the instructions and guidelines of the LUMC
medical ethics committee, in accordance with the Helsinki
Declaration, as regulated and approved by the LUMC MDL
biobanking protocol CuraRata. The control samples were
provided by the Center for Neurobiology of Stress in the Di-
vision of Digestive Diseases at the University of California–Los
Angeles (UCLA) or by the Department of Gastroenterology
and Hepatology at LUMC. All experiments were approved by
the institutional review boards of all the institutions.
Human Samples for Tissue Microarrays
The study cohort consisted of samples from 20 randomly
selected CRC patients who underwent surgery for tumor
removal. The control group included ﬁve samples from
adjacent morphologically normal tissue. The study was
approved by the ethics committee of the Hospital Infantil de
México Federico Gomez (Mexico City, Mexico; HIM/2007/
061). Both CRC and normal samples were collected between
2002 and 2007 from the Department of Pathology of
Hospital General Regional No. 25, IMSS and Speciality
Hospital CMN La Raza, IMSS (Mexico City, Mexico). All CRC
cases were classiﬁed according to the Dukes or TNM
Table 1.Colorectal Cancer Patient Clinicopathologic Characteristics Used for the mRNA Analysis of Corticotropin-Releasing
Hormone Family Members
Characteristicsa Cases (n ¼ 56)
CRHR2 Ucn2
Mean ± SEM P Value Mean ± SEM P Value







Dukes classiﬁcation NS NS
A 1 1.28 ± 0.0 3 ± 0.0
B1 þ B2 17 0.8 ± 0.52 45 ± 13.7
C1 þ C2 29 0.67 ± 0.25 54.8 ± 17
D 9 0.68 ± 0.53 47.8 ± 27.5
TNM classiﬁcation NS NS
Low 18 0.83 ± 0.5 42.65 ± 13.2
High 38 0.67 ± 0.22 53.16 ± 14.4
Differentiation NS NS
Well 7 0 ± 0.0 58.41 ± 33
Moderate 18 0.79 ± 0.44 24.67 ± 6.4
Poor 31 0.84 ± 0.29 62.42 ± 17
Metastasisb .047 NS
NM 21 1.37 ± 0.47 51.69 ± 15
DM 18 0.36 ± 0.21 46.5 ± 13.3
Body mass indexb .048a NS
Underweight (<18.5) 3 0 ± 0.0 16.8 ± 11
Normal (18.5–24.9) 23 1.07 ± 0.41 41.91 ± 9.2
Overweight (25–29.9) 13 0.06 ± 0.06 69.87 ± 31.6
Obese (>30) 3 1.21 ± 0.92 145.3 ± 111
Note: CRHR2, corticotropin-releasing hormone receptor 2; DM, distant metastasis; NM, no metastasis; NS, not statistically
signiﬁcant (P > .05); SEM, standard error of the mean; TNM, tumors/nodes/metastases; Ucn2, urocortin-2.
aNormal weight versus overweight.
bInformation was not available for all cases.
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and use was approved by the ethics committee of the
Hospital Infantil de México Federico Gomez. Tissue micro-
arrays (TMAs) were constructed as follows: formalin-ﬁxed,
parafﬁn-embedded archival tumor specimens were pre-
pared at the Immunology and Infection Research Unit, Na-
tional Medical Center La Raza and at the Oncology Disease
Research Unit, Hospital Infantil de México Federico Gomez.
At least three core tissue biopsies (each 0.6 mm in diameter)
were taken from morphologically representative regions of
each colorectal tumor and precisely arrayed according to
the microarray technique with a semiautomatic ATA-100
Chemicon system (advanced tissue array; Chemicon,
Temecula, CA), as previously described elsewhere.18 Tissues
were arrayed into ﬁve TMA blocks. For staining, sections (4
mm) were transferred to glass slides using an adhesive slide
system (PSA-CS 4; Instrumedics, St. Louis, MO) to support
cohesion of the array elements.Cell Treatments
Cells were treated with the CRHR2-speciﬁc agonist
urocortin-2 (Ucn2, H-5852; Bachem, Torrance, CA), theCRHR2 speciﬁc antagonist astressin-2B (Ast2B, cat. no.
2391; Tocris Bioscience, Bristol, United Kingdom) and
interleukin-6 (IL-6, CYT-213; ProSpec-Tany Technogene,
East Brunswick, NJ) used either as single agents or in
combination at the indicated concentrations of each exper-
imental condition. All cell treatments were performed in
media containing 0.1% FBS. Before treatment, the cells
remained in serum-deprived media for overnight
incubation.Gene Expression Analysis
Total RNA was extracted from tissues and cell
lines using the RNeasy Plus Universal Mini kit (cat. no.
73404; Qiagen, Valencia, CA) and RNeasy Plus Mini Kit
(cat. no. 74134; Qiagen), respectively. cDNA was synthe-
sized using the quantitative reverse-transcription kit (cat.
no. 205311; Qiagen). Quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) was performed
using TaqMan universal PCR master mix (4352042; Applied
Biosystems, Foster City, CA) and on-demand gene-
speciﬁc primers (Applied Biosystems). Primer sets in-
cluded the following: CRHR1 (Hs00366363_a1), CRHR2
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49155_s1), Ucn2 (Hs00264218_s1), Ucn3 (Hs00846
499_s1), IL-6 (Hs00985639_m1), IL-6R (Hs01075666_m1),
IL-1b (Hs01555410_m1), Vim (Hs00958116_m1), CDH1
(Hs01023894_m1), and 18S (Hs99999901_s1). The re-
actions were run in an ABI 7500 Fast RT-PCR system
(Applied Biosystems) and were analyzed using SDS software
(version 1.3; Applied Biosystems). Relative quantiﬁcation
was achieved by normalizing to gene expression of 18S.
Transient Transfections
SW620 and SW480 cells cultured in 24/well plates at
50–60% conﬂuence were transfected with 30 pmol/well of
small interfering RNA (siRNA) against Ucn2 (cat. no. Sc-
106676; Santa Cruz Biotechnology, Santa Cruz, CA) or
scramble control siRNA (cat. no. Sc-37007; Santa Cruz
Biotechnology) using Lipofectamine RNAiMAX (cat. no.
13778075; Invitrogen). No cell toxicity was detected owing
to the transfection agent. The RNA was extracted 72 hours
after transfection for qRT-PCR.
For plasmid transfections, SW480-EV and SW480-
CRHR2þ cells cultured at 70% conﬂuence were trans-
fected with 2 mg of pCDNA3.1-SnailS6A or pCDNA3.1,
respectively, using Lipofectamine 2000 (cat. no. 11668019;
Invitrogen). Mutated SnailS6A protein is more resistant to
ubiquitination-dependant proteosome degradation. Twenty-
four hours later, cells were transferred to 96-transwells and
incubated for 48 hours with 15 ng/mL of recombinant hu-
man transforming growth factor b1 (TGFb1, cat. no.
PHG9204; Invitrogen) ± 0.1 mM Ucn2 for determination of
cell migration. All transfections were performed in
triplicate.
Lentiviral Transductions
Construction of CRHR2-expressing lentivirus and stable
cell transduction were performed as described previously
elsewhere.19 Brieﬂy, the cells were infected with MCS-IRES-
Strawberry-hPGK-Puro lentivirus particles containing a
cytomegalovirus promoter driving expression of human
CRHR2 (A0634; GeneCopoeia, Rockville, MD) or scramble
negative control (EV, empty virus). Selection of transduced
clones was performed in culture medium containing 10
mg/mL of puromycin. Only the highly ﬂuorescent cell clones
were used in the experiments.
Anchorage-Independent Growth Assay
Triplicates of 5  105 CRC cells were mixed 4:1 (v/v)
with 2% agarose in growth medium (ﬁnal, 0.4% agarose).
Cell mixtures were plated on a layer of medium containing
0.5% agarose and fed every 6–7 days (0.4% agarose); col-
onies were counted after 15 days. Where appropriate, 0.1
mM Ucn2 was added every 2 days.
Western Blot Analysis
Western blot analysis in protein lysates derived by cell
lines was performed as previously described elsewhere.20
Brieﬂy, sodium dodecyl sulfate polyacrylamide gelelectrophoresis (SDS-PAGE) was conducted using 8–12%
gradient Tris-glycine gels (Invitrogen) and loaded with 30
mg of total protein lysates. Membranes were blocked in Tris-
buffered saline (TBS) þ 5% nonfat milk, and primary and
secondary antibodies were incubated overnight at 4C or for
2 hours at room temperature, respectively, in TBS þ 0.1%
Tween-20 þ 5% nonfat milk; phospo-signal transducer and
activator of transcription 3 (pStat3) was incubated in TBS þ
0.1% Tween-20 þ 5% bovine serum albumin (BSA). Pri-
maries used were b-actin ms (1:1000, cat. no. 130065; Santa
Cruz Biotechnology), pStat3 (Tyr705) rb (1:1000, cat. no.
9145S; Cell Signaling Technology, Beverly, MA), b-catenin rb
(1/3000, cat. no. ab6302; Abcam, Cambridge, MA), vimentin
ms (1/2000, ab8069; Abcam), E-cadherin rb (1/500,
ab53033; Abcam), ZEB1 rb (1/500, cat. no. SAB3500514;
Sigma-Aldrich, Saint Louis, MO), and CRHR2 (1/1000, cat.
no. ABN433; Millipore, Temecula, CA). Horseradish perox-
idase–tagged IgG secondary antibodies were anti-mouse
(cat. no. sc2005; Santa Cruz Biotechnology) or anti-rabbit
(cat. no. sc2004; Santa Cruz Biotechnology) used at
1/2000 dilution. Chemiluminescence was detected with
enhanced reagent (cat. no. 34080; ThermoScientiﬁc, Rock-
ford, IL) using an Eastman Kodak 440 Imaging System
(Kodak, Rochester, NY). Beta-actin was used as a loading
control.Immunohistochemistry
Tumors resected via SW620-bearing mice were ﬁxed in
4% formaldehyde in phosphate-buffered saline (PBS) and
embedded in parafﬁn blocks. We cut 2-mm sections, placed
them on slides, and used them for Mayer’s H&E staining or
for immunohistochemical (IHC) analysis, as previously
described elsewhere.21 Slices cut at 4 mm for the TMAs were
placed on slides, and they were either H&E stained for
histopathologic examination or used for subsequent IHC
analysis. In all cases, antigen retrieval was performed after
tissue deparafﬁnization and hydration by immersing the
slides in a solution of 0.01% sodium citrate (pH 6.0) for 5
minutes in boiling water. Endogenous peroxidase activity
was inhibited by immersing the slides in 3% H2O2-meth-
anol, and background-unspeciﬁc binding was decreased by
incubating the slides in 2% BSA (Sigma-Aldrich, St. Louis,
MO) in PBS for 60 minutes. Primary antibodies were incu-
bated at room temperature overnight. The primaries used
were Raf-1 kinase inhibitory protein (RKIP) ms (1:500, cat.
no. sc-365973; Santa Cruz Biotechnology), pStat3(Tyr705)
rb (1:250, cat. no. 9145S; Cell Signaling Technology), N-
cadherin rb (1/500, cat. no. ab18203; Abcam), vimentin ms
(1/250, cat. no. ab8069; Abcam), vascular endothelial
growth factor (VEGF) rb (1/200, cat. no. ab46154; Abcam),
Snail rb (1/100, cat. no. ab135708; Abcam), proliferating
cell nuclear antigen (PCNA) ms (1:4000, cat. no. 2586S; Cell
Signaling Technology), and CRHR2 rb (1/750, cat. no.
ABN433; Millipore). To decrease variability, all samples
were processed at the same time in a single experiment,
using a single batch of antibody diluted in PBS-BSA.
After washing, the slides were incubated with a bio-
tinylated secondary antibody (Universal LSAB kit; Dako
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perature, followed by incubation with a streptavi-
din–horseradish peroxidase conjugate (Universal LSAB kit)
for 30 minutes at room temperature and then with 3,30-
diaminobenzidine tetra-hydrochloride (liquid DAB; Dako
Corporation). The reaction was stopped by adding distilled
water, and the slides were counterstained with H&E. The
tissue was washed in tap water for 5 minutes, dehydrated
using an ethanol series (70%, 90%, and 100%) and xylene
and mounted with E-2 mounting medium (Shandon Labo-
ratory, Pittsburgh, PA). The slides were examined by light
microscopy (Olympus BX-40; Olympus Corporation, Tokyo,
Japan), and then expression intensity (brown color) in the
total section area (mm3) was evaluated by digital image
analysis as described herein.
Analysis of Immunohistochemical Digital Images
Immunohistochemically stained sections were digitized
at 40 magniﬁcation using an Aperio Scanscope CS (Aperio,
Vista, CA). The Aperio Scanscope CS obtains 40 magniﬁ-
cation images with a spatial resolution of 0.45 mm/pixels.
Once the areas were annotated, they were sent for auto-
mated image analysis using Spectrum software (Aperio),
and an algorithm was developed to quantify the total
expression of the target protein. The output from the algo-
rithm returns a number of quantitative measurements such
as intensity, concentration, and percentage of positive
staining present. The quantitative scales of intensity and
percentage were categorized to four and ﬁve classes,
respectively, after the cutoff values were determined. The
intensity of staining was categorized as 0 (no staining), 2þ
(moderate), and 3þ (strong). The ﬁnal IHC score was
calculated from a combination of the intensity and per-
centage scores.
In Vitro Migration and Invasion Assays
The invasive and migratory potentials of SW620 and
HCT116 cells were assessed using Cultrex 96-transwell as-
says containing inserts with 8-micron polyethylene tere-
phthalate membranes and according to the manufacturer’s
instructions (3465-096-K; 3455-096-K; Trevigen, Gaithers-
burg, MD). Brieﬂy, to analyze invasion, the inserts were
ﬁrst coated with 50 mL of 0.5X basement membrane
extract solution and incubated overnight at 37C. Subse-
quently, 5  104 EV or CRHR2þ cells, previously deprived of
serum (0.1%), were seeded into the upper chambers in
serum-free medium supplemented with 0.1 mM Ucn2, alone
or in combination with 1 mM Ast2B in the presence or
absence of 20 ng/mL IL-6. Medium supplemented with 15%
FBS was applied to the lower chambers as a chemo-
attractant to induce invasion/migration.
The chambers were incubated at 37C in a 5% CO2
incubator for 48 hours. At the end of incubation, the inserts
were extensively washed, and the cells that invaded were
labeled with 5 mg/mL of calcein acetomethylester diluted in
cell dissociation solution at 37C for 1 hour. Fluorescence
was measured at 485 nm in a Wallac 1420 Victor2 multi-
label plate reader (Perkin-Elmer, Shelton, CT). In themigration assay, the same procedure of invasion assay was
followed, except that inserts were not coated with basement
membrane extract. For detecting IL-6-induced invasion and
migration of DLD1, the cells were pretreated with 20 ng/mL
IL-6 for 72 hours as previously described elsewhere.22
Migration and invasion were monitored using 24-well
transwell chambers.
Monitoring Invasion and Migration of DLD1 Cells
The invasion and migration assays of IL-6-pretreated
DLD1 cells were performed using Matrigel Invasion Cham-
bers (8-micron pore size membrane) (cat. no. 354480;
Corning, Bedford, MA) and transwell permeable supports
(8-micron polycarbonate membrane) (cat. no. 3422; Costar,
Corning, NY), respectively. Brieﬂy, serum-deprived cells
were collected with Accutase (cat. no. A11105-01; Life
Technologies, Grand Island, NY) and seeded at a concen-
tration of 5  104 cells in each upper chamber in serum-free
medium supplemented with 0.1 mM Ucn2 alone or in com-
bination with 1 mM Ast2B. As a chemoattractant, 20% FBS
was placed in the lower chamber. Control inserts were
included in all assays (cat. no. 354578; Corning).
After 72 hours, the nonmotile/invasive cells in the
chambers were wiped away using a cotton swab, and the
invaded/migrated cells were ﬁxed and stained with 0.5%
crystal violet solution containing 20% methanol. After
multiple washes, the membranes were cut, air dried,
mounted on slides, and observed under a microscope. For
each sample, six random optical ﬁelds at 10 magniﬁcation
were analyzed to determine the mean number of invading/
migrating cells. Photographs were taken with an inverted
Imager Z.1 microscope (Carl Zeiss Microscopy GmbH, Jena,
Germany) equipped with an AxioCam HRc camera (Carl
Zeiss Microscopy) and analyzed with the accompanying
AxioVision software.
cAMP Determination
Ucn2 dose-response studies related to cAMP production
were performed in parental and CRHR2þ CRC cells using the
Direct cAMP Enzyme Imunoassay Kit (cat. no. 901-066;
Assay Designs, Ann Arbor, MI). Cells were stimulated with
Ucn2 (109 to 106 M) for 30 minutes. After removal of
media, cells were lysed for 20 minutes in 1 mL 0.1M HCl.
Cell lysates were centrifuged at 600g at room temperature
for 5 minutes and cAMP levels determined in 50 mL su-
pernatant samples using triplicate wells and duplicate as-
says for each treatment.
Ucn2 Protein Determination
Ucn2 protein secreted by different CRC and NCM460 cell
lines was quantiﬁed by an enzyme-linked immunosorbent
assay kit (cat. no. MBS2023605; MyBioSource, San Diego,
CA) according to the manufacturer’s instructions with slight
modiﬁcations. Brieﬂy, serum-free conditioned media were
collected from cells seeded in 35-mm wells. We incubated
100 mL of undiluted cell culture supernatants in precoated
wells in enzyme-linked immunosorbent assay plate at 4C
overnight. Subsequent procedures for target protein
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instructions. The concentration of Ucn2 secreted to the
culture medium was measured at optical density at 450 nm
and normalized by the total amount of protein in cell lysates
harvested by each well.
Cell Proliferation Assay
Cell proliferation was quantiﬁed by a colorimetric XTT-
based assay (cat. no. 11465015001; Roche Applied Sci-
ence, Indianapolis, IN). Brieﬂy, 4  103 EV or CRHR2þ cells
were plated in 96-well plates and allowed to adhere for 24
hours. Then cells were treated with 0.1 mM Ucn2 alone or in
combination with 1 mM Ast2B in presence or absence of
20 ng/mL IL-6 for 72 hours. At the end of incubation, 50 mL
of XTT labeling mixture was added to each well, and the
cells incubated at 37C for 4 hours. Cell growth was deter-
mined by measuring absorbance at 570 nm in a Wallac 1420
Victor2 multilabel plate reader (Perkin-Elmer).
xCELLigence Real-Time Cell Analysis
Technology
To access NCM460 proliferation and migration under
various conditions, we used a label-free real-time cell anal-
ysis platform (xCELLigence; Roche Applied Science). Brieﬂy,
for cell proliferation 100 mL of complete culture medium at
room temperature was added into each well of E-plate 96.
After this the E-plate 96 was connected to the system and
checked in the cell-culture incubator for proper electrical
contacts, and the background impedance was measured
during 24 seconds. Meanwhile, NCM460-EV and NCM460-
CRHR2 cells were resuspended in complete culture me-
dium and adjusted to 10,000 cells/mL (previously deter-
mined optimal seeding concentration). We added 100 mL of
each cell suspension to the 100 mL-medium-containing wells
on E-plate 96. After 30 minutes of incubation at room tem-
perature, E-plate 96 was placed into the cell culture incu-
bator. Approximately 24 hours after seeding, when the cells
were in the log growth phase (cell index >0.5), the 100 mL of
medium was removed from each well and replaced with 100
mL of complete medium containing Ucn2, Ast2B, or the
combination. Controls received medium only. Cell prolifera-
tion was monitored every 15 minutes for a period of up to
72 hours via the incorporated sensor electrode arrays of the
E-Plate 96. The electrical impedance was measured by the
real-time cell analysis–integrated software of the xCELLi-
gence system as a dimensionless parameter termed “CI.”
The rate of NCM460-EV and NCM460-CRHR2 cell
migration was also monitored in real-time with the xCEL-
Ligence system (CIM-plate 16). At 24 hours before we con-
ducted the experiment, the cells were serum starved. We
added 100 mL of complete culture medium into the lower
chamber and 50 mL of serum-free medium into the upper
chamber. The plate was inserted into the platform and left
for incubation for no more than 1 hour. Meanwhile, dilutions
of 1  106 cells/mL plus the appropriate factors (Ucn2,
Ast2B, or the combination) were prepared in serum-free
medium. We added 100 mL of each cell suspension in each
well of the upper chamber and left it to equilibrate at roomtemperature for 30 minutes. The impedance value of each
well was automatically monitored by the xCELLigence sys-
tem for a duration of 50 hours and expressed as a “CI” value.
Superarray Analysis
The EV and CRHR2þ SW620 and SW480 cells were
treated with 20 ng/mL IL-6 and 0.1 mM Ucn2 for 18 hours.
The RNA was isolated as described earlier, and the
expression proﬁles of 84 genes related to cell cycle and 84
genes related to epithelial-to-mesenchymal transition (EMT)
were determined using 96-well format RT2 Proﬁler PCR
arrays (PAHS-020Z; PAHS-090Z; SABiosciences/Qiagen,
Frederick, MD) including six housekeeping genes and three
RNAs as internal controls. The qRT-PCRs were run on an
ABI 7500 Fast qPCR instrument (Applied Biosystems) with
SDS software using RT2 SYBR Green qPCR Mastermix
(cat. no. 330522; SABiosciences/Qiagen). Data analysis
was performed using the 2DCt method described on the
manufacturer’s Web site (www.SABiosciences.com/
pcrarraydataanalysis.php). Heat maps of the relative gene
expression were generated using the online Hierarchical
Clustering Explorer (HCE) software.




Apoptosis in tissue sections was assessed using In Situ
Cell Death Detection Kit, POD (11684817910; Roche Applied
Science) according to the manufacturer’s instructions.
In Vivo Mouse Xenograft Model
Eight-week-old athymic nude mice were used for moni-
toring SW620-CRHR2þ and SW620-EV growth in vivo under
various treatment protocols. Brieﬂy, 1  106 SW620-EV or
SW620-CRHR2þ cells diluted in 100 mL PBS were injected
subcutaneously into the right hind limb under sevoﬂurane
anesthesia. When animals developed palpable tumors
(50–100 mm3), mice from each tumor group were randomly
assigned to the following subgroups: 1) Ucn2-treated (15
mg/kg; n ¼ 5) intratumorally every 2 days for 2 weeks;
2) Ucn2þAst2B-treated (15 mg/kg þ 30 mg/kg; n ¼ 5)
intratumorally with every 2 days for 2 weeks; and 3) vehicle
control (0.1% acetic acid in PBS; n ¼ 5). Tumor volume was
measured with a caliper weekly and calculated with the
following formula: A (length)  B (width)  C (height) 
0.5236. Treatment efﬁcacy was evaluated by change in tu-
mor volume. After treatment, the mice were euthanized, and
the tumors were harvested for histologic studies. All animal
experiments were done in accordance with institutional
guidelines for animal welfare.
Processing of Digital Images
Adobe Photoshop CS6 software (Adobe Systems, Moun-
tain View, CA) was used as a digital tool to 1) adjust
contrast, brightness, or color, in digital images after uniform
application to the entire image, 2) crop unneeded fractions
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derived IHC digital images based on the formula: Actual
Pixel size ¼ CCD Pixel  Binning/Lens Magniﬁcation  C
mount  Objective Magniﬁcation.
Statistical Analysis
Statistical and Kaplan-Meier survival analyses were
performed with GraphPad Prism Software (version 5;
GraphPad Software, La Jolla, CA). Statistical differences be-
tween two groups were determined by Student t test. Dif-
ferences between multiple groups were determined using
analysis of variance (ANOVA). P  .05 was considered sta-
tistically signiﬁcant. Data are expressed as the mean ±
standard error of the mean (SEM).
Results
Diminished Corticotropin-Releasing Hormone
Receptor 2 and Elevated Urocortin-2 Expression
in Colorectal Cancer Tissues and Cell Lines
We explored the expression of CRH family members in
CRC human tissues (n ¼ 56) (Table 1) and normal controls(N ¼ 46). We found statistically signiﬁcantly decreased
CRHR2 mRNA levels (P < .0001) (Figure 1A) and elevated
Ucn2 expression (P ¼ .016) in CRC tissues compared with
normal controls (Figure 1B). None of the other CRH family
members showed any statistically signiﬁcant differences in
expression between CRC and control tissue groups
(Table 2). CRH was not detectable in any group. The
reduced CRHR2 expression in CRC was also conﬁrmed by
IHC at the protein level in 20 CRC samples compared with
ﬁve normal controls (Figure 1C). Representative CRHR2
staining in CRC and normal tissues is shown in Figure 1D.
We performed the same analysis in human CRC cell lines
(N ¼ 7) and the immortalized colonic epithelial cell line
NCM460. Compared with NCM460, all tested cell lines had
statistically signiﬁcantly lower CRHR2 mRNA expression
(Figure 2A) (fold decrease range: 50–350), and Ucn2 mRNA
levels were found to be statistically signiﬁcantly up-regulated
in four out of seven CRC cell lines tested (Figure 2B) (fold
increase range: 2–13). CRHR2 protein levels were also
monitored in these cell lines by Western blot analysis, con-
ﬁrming the down-regulated expression in most CRC cell lines
tested compared with NCM460 (Figure 2C).Figure 1. Corticotropin-
releasing hormone recep-





signiﬁcant inhibition (***P <
.001) of CRHR2 mRNA
levels in CRC tissues (n ¼
56) compared with normal
controls (n ¼ 46). (B) Sta-
tistically signiﬁcant over-
expression (*P ¼ .016) of
Ucn2 mRNA in CRC tis-
sues (n ¼ 56) compared
with normal controls (n ¼
46). (C) CRHR2 protein
down-regulation in CRC
tissues (n ¼ 20) over
normal (n ¼ 5) (P ¼ .0001).
(D) Representative CRHR2
staining in CRC and normal
tissue arrays. Original
magniﬁcation 20, scale
bar: 50 mm (scale bar
proportional to the ori-
ginal microscope-derived
image).
Table 2.mRNA Expression of Corticotropin-Releasing
Hormone Peptides and Receptors in Normal and
Colorectal Cancer Human Tissues
Peptide CRC (n ¼ 56) Normal (n ¼ 46) P Value
CRHR1 0.28 ± 0.11 0.42 ± 0.23 NS
CRHR2 0.72 ± 0.21 10.55 ± 2 <.0001
Ucn1 20.69 ± 2.9 23.72 ± 3 NS
Ucn2 49.74 ± 10.6 17.2 ± 7 .0161
Ucn3 26.4 ± 4.5 37.56 ± 3.4 NS
Note: Values are mean ± standard error of the mean. CRHR,
corticotropin-releasing hormone receptor; NS, not statisti-
cally signiﬁcant (P > .05); Ucn, urocortin.
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versus NCM460 cells was further validated at the protein
level in cell culture supernatants (Figure 2D). With the
exception of HCT116, no statistically signiﬁcant differences
were observed in CRHR1 mRNA expression between the
CRC cell lines and NCM460 (Table 3), whereas the Ucn1 and
Ucn3 expression proﬁles followed a cell line-dependant in-
crease or decrease compared with NCM460 (Table 4). These
ﬁndings show statistically signiﬁcant differences in CRHR2
and Ucn2 expression between malignant and normal colonic
cells that might reﬂect dysregulated CRHR2/Ucn2 signaling
in CRC.Corticotropin-Releasing Hormone Receptor 2/
Urocortin-2 Signaling Inhibits Colorectal Cancer
Proliferation, Migration, Invasion, and Colony
Formation
To test the impact of CRHR2/Ucn2 imbalance in CRC
pathophysiology, including tumor growth and EMT occur-
rence, we stably transduced SW480, SW620, DLD1, and
HCT116 (cell lines with diminished CRHR2 and elevated
Ucn2 expressions versus NCM460 cells) with CRHR2-
expressing lentivirus. Validation of CRHR2 overexpression
(CRHR2þ) over parental (EV) cells was performed using
qRT-PCR (Figure 2E); conﬁrmation of receptor activity upon
stimulation with its selective agonist Ucn2 was shown by
increased cAMP production (Figure 2F). Interestingly, Ucn2
mRNA levels in SW480 and SW620 cells were statistically
signiﬁcantly decreased after CRHR2 induction, suggesting
that Ucn2 and CRHR2 expressions might share overlapping
regulatory mechanisms (Figure 2G); however, this is beyond
the focus of our present study.
We initially compared the proliferation responses of
SW480 and SW620 cells transduced with CRHR2 with those
of the corresponding EV cells before and after stimulation
with Ucn2 (Figure 3A). Both CRHR2þ cell lines had statis-
tically signiﬁcantly decreased baseline proliferation
compared with EV cells, suggesting that endogenous Ucn2
levels are effective in stimulating CRHR2 signaling to
mediate its antiproliferative effects. This inhibition was
more pronounced in the presence of exogenous Ucn2. The
observed Ucn2-mediated inhibition of CRHR2þ proliferationwas reversed by Ast2B, a selective CRHR2 antagonist,
demonstrating that this effect is CRHR2 speciﬁc. No statis-
tically signiﬁcant changes were observed in the proliferation
of parental cells after treatment with 0.1 mM Ucn2.
In contrast, treatment of NCM460 with Ucn2 did not
statistically signiﬁcantly increase the baseline cell prolifer-
ation; however, CRHR2 overexpression in those cells alone
or combined with Ucn2 treatment increased speciﬁcally the
proliferative response, suggesting that CRHR2/Ucn2
signaling might interfere differently with cell cycle regula-
tors in normal and malignant colonic cells (Figure 3B).
Concomitantly with the proliferation ﬁndings, the baseline
colony formation was decreased in CRHR2þ SW460 and
SW480 cells (Figure 3C). However, CRHR2þ cell treatment
with Ucn2 did not further reduce colony formation in both
cell lines.
We next tested the migratory and invasive properties of
SW620 and HCT116 after CRHR2 induction. Similarly to cell
proliferation, both invasion (Figure 3D) and migration
(Figure 3E) of these cells were negatively affected by CRHR2
overexpression, reaching the lowest level after treatment
with Ucn2. Although Ucn2 also mediated inhibition of the
invasion and migration of HCT116 parental cells, this
response was not CRHR2 speciﬁc because cell treatment
with Ast2B was able to reverse the inhibitory effect only in
CRHR2þ cells. Migration of parental NCM460 was not
affected by Ucn2; however, cell treatment with the CRHR2
antagonist Ast2B (with or without Ucn2) enhanced both the
baseline and Ucn2-mediated migration, thus suggesting that
CRHR2 levels might speciﬁcally affect NCM460 migration
but not exclusively through Ucn2 ligation (Figure 3F). In
contrast, NCM460 overexpressing CRHR2 had higher
migratory potential than parental NCM460 that was further
enhanced by Ucn2 and reversed by Ast2B (Figure 3F). These
results further support the notion previously addressed that
CRHR2/Ucn2 signaling might interfere differently with
regulators of cell growth and migration in normal and ma-
lignant CRC cells.
Furthermore, to explore the contribution of CRHR2/
Ucn2 signaling in regulating EMT induction in non-
metastatic CRC cells, we monitored the migration rates of
SW480-CRHR2þ and SW480-EV cells transfected with Snail
in the presence of TGFb1 with or without Ucn2 treatment
(Figure 3G). Transfection of both clones with the
degradation-resistant SnailS6A mutant increased the
migration rates after all treatments. As expected, cell
migration was further enhanced by exposure to TGFb1.
However, compared with the SnailS6A-expressing EV cells,
SnailS6A-expressing CRHR2þ cells had lower responses to
TGFb1 and a further reduction in the presence of Ucn2. In
addition, Ucn2 inhibited only the TGFb1-mediated migration
of SnailS6A-expressing CRHR2þ cells.
These observations suggest that CRHR2/Ucn2 signaling
interferes negatively with both the metastatic potential of
CRC cells that have already undergone EMT and the potency
of EMT progression in epithelial CRC cells under optimal
conditions. Our overall ﬁndings imply CRHR2/Ucn2
signaling as a putative negative regulator of tumor growth
and oncogenic EMT in CRC.
Figure 2. Corticotropin-
releasing hormone re-




cell lines. (A) Statistically
signiﬁcant inhibition of
CRHR2 mRNA expression
in seven CRC cell lines
(SW480, SW620, SW403,
HT29, DLD1, HCT116, and
CaCo2) compared with
an immortalized colonic
epithelial cell line NCM460.
*P < .05; **P < .01. (B)
Ucn2 is statistically signiﬁ-
cantly overexpressed in
the CRC cell lines com-
pared with NCM460.
*P < .05. (C) Representative
Western blot showing
CRHR2 down-regulation at
the protein level in CRC cell
lines over NCM460. Densi-
tometric analysis corre-
sponds to the presented
Western blot. Lanes of
bands shown have been
cropped from the original
whole gel image. (D) Fold
change of Ucn2 protein
expression in CRC cell cul-
ture supernatants com-
pared with NCM460. **P <
.01; ***P < .001. (E) CRC









merase chain reaction. EV
stands for parental cells
transduced with an empty
(CRHR2) virus. (F) Statisti-
cally signiﬁcant elevation
of cAMP production in
CRHR2þ versus EV cells
as response to increasing
Ucn2 concentrations. **P <
.01. (G) CRHR2 induction
lowers Ucn2 baseline
mRNA levels in SW480 and
SW620 cells. *P < .05.
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Table 3.mRNA Expression of Corticotropin-Releasing
Hormone Receptors in NCM460 and Colorectal
Cancer Cell Lines (N ¼ 7)
Cell Line
CRHR1 CRHR2
Mean ± SEM P Value Mean ± SEM P Value
NCM460 0.07 ± 0.06 1.95 ± 0.19
SW480 0.06 ± 0.03 NS 0.01 ± 0.00 <.0001
SW620 2.03 ± 0.4 NS 0.01 ± 0.00 .01
SW403 0.32 ± 0.25 NS 0.14 ± 0.12 .001
HT29 2.79 ± 2.7 NS 0.007 ± 0.001 <.0001
DLD1 0.17 ± 0.02 NS 0.007 ± 0.002 <.0001
HCT116 3.22 ± 0.1 .001 0.008 ± 0.001 <.0001
CaCo2 0.07 ± 0.06 NS 0.38 ± 0.36 .048
Note: P values are NCM460 versus colorectal cancer cell
lines. CRHR, corticotropin-releasing hormone receptor; NS,
not statistically signiﬁcant (P > .05); SEM, standard error of
the mean.
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Urocortin-2 Signaling Inhibits Colorectal Cancer
Growth and Epithelial-to-Mesenchymal
Transition in Vivo
The impact of CRHR2 overexpression on CRC prolifera-
tion and EMT rates was validated in vivo in mice bearing
SW620-CRHR2þ or SW620-EV xenografts. Tumor volume
was assessed under different conditions (with or without
Ucn2 and/or Ast2B) (Figure 4A). CRHR2þ tumors were
smaller and volume was further reduced after Ucn2
administration. Ast2B reversed this effect, suggesting that
inhibition of tumor growth was CRHR2 dependent. We also
found increased necrosis and apoptosis as well as reduced
PCNA expression in CRHR2þ tumors, as assessed by H&E
(Figure 4B), terminal deoxynucleotidyl trans-
ferase–mediated digoxigenin-deoxyuridine nick-end label-
ing (Figure 4C), and IHC (Figure 4D) stainings, respectively.
The magnitude of these changes was increased with
Ucn2 administration. EMT-inducing gene products such asTable 4.mRNA Expression of Corticotropin-Releasing Hormone
Cell Line
Ucn1
Mean ± SEM P Value Mean ±
NCM460 30.24 ± 1.2 — 0.98 ±
SW480 3.43 ± 0.07 .002 10.97 ±
SW620 169.7 ± 3.4 <.001 12.64 ±
SW403 65.55 ± 6.9 .035 0.84 ±
HT29 18.52 ± 0.32 .01 0.19 ±
DLD1 25.74 ± 1.6 NS 4.46 ±
HCT116 19.37 ± 0.63 .015 1.64 ±
CaCo2 1.5 ± 0.16 .002 0.54 ±
Note: P values are NCM460 versus colorectal cancer cell line
statistically signiﬁcant (P > .05); SEM, standard error of the mevimentin, N-cadherin, and Snail were down-regulated in
CRHR2þ tumors derived by Ucn2-treated mice accompanied
by increased expression of the EMT-suppressor RKIP
(Figure 4E). Ucn2-treated CRHR2þ tumor specimens had
also decreased VEGF expression, suggesting that angiogen-
esis could be a possible target of CRHR2/Ucn2 signaling
(Figure 4E). These observations validate our in vitro ﬁnd-
ings on the role of CRHR2 in suppression of CRC prolifera-
tion and EMT, at least at the molecular level.
Corticotropin-Releasing Hormone Receptor 2
Induction Inhibits Proinﬂammatory Cytokine
Expression and Interleukin-6-Mediated pSTAT3
Activation in Colorectal Cancer
Several molecular events in chronic inﬂammation
contribute to multistage CRC carcinogenesis and progres-
sion in the inﬂamed colon, including up-regulated proin-
ﬂammatory cytokines such as IL-1b, IL-6, IL-8, and tumor
necrosis factor a (TNFa) expressed by colonic and inﬁl-
trating immune cells.23 Given the involvement of the CRH-
family in regulating colonic inﬂammation,3,4 we hypothe-
sized that the effects of CRHR2/Ucn2 signaling in CRC
proliferation, migration, and invasion might be driven by
CRHR2-dependent changes in the inﬂammatory proﬁle of
CRHR2þ CRC cells. As such, we compared the expression of
proinﬂammatory cytokines between parental (EV) and
CRHR2þ cells.
Among the cytokines screened in CRHR2þ cells we
detected reduced levels of IL-1b and IL-6 mRNA (Figure 5A),
as well as inhibition of IL-6R mRNA expression (Figure 5B).
Notably, inhibition of the proinﬂammatory cytokines IL-6,
IL-1b, and IL-8 was also observed in CRC cells after Ucn2
silencing by siRNA (Figure 5C), in parallel with CRHR2 up-
regulation (Figure 5D). IL-6 and IL-6R mRNAs were also
found elevated in CRC samples compared to healthy con-
trols (Figure 5E). Our overall in vitro ﬁndings suggest
CRHR2 as a negative mediator of proinﬂammatory signals
produced by the CRC cells, which might contribute to their
expansion and progression. In addition, excess production
of Ucn2 by CRC cells might contribute to sustaining colonicAnalogs in NCM460 and Colorectal Cancer Cell Lines (n ¼ 7)
Ucn2 Ucn3
SEM P Value Mean ± SEM P Value
0.01 — 0.43 ± 0.009 —
1.4 .02 0.0 ± 0.0 <.001
0.6 .003 20.26 ± 5.03 .058
0.17 NS 0.35 ± 0.05 NS
0.01 <.001 1.9 ± 0.13 .009
0.001 <.001 5.24 ± 0.65 .018
0.14 .04 0.0 ± 0.0 <.001
0.15 NS 0.1 ± 0.1 NS
s. CRHR, corticotropin-releasing hormone receptor; NS, not
an.
620 Rodriguez et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 6inﬂammation, possibly through targeting other cells in the
tumor microenvironment.
Inﬂammation targets several main regulators of cell
growth, invasion, and angiogenesis, including Stat3.24 In
CRC in vivo models, Stat3 down-regulation decreases
tumorigenicity and cell growth.18,24 We explored the effects
of CRHR2-induction on IL-6-mediated Stat3 activation in
CRC because Stat3 is a major downstream target of IL-6/IL-
6R signaling and is constitutively active in almost all cancers
including CRC.18
SW620-, DLD1- and SW480-CRHR2þ clones had
decreased Stat3 (Tyr705) phosphorylation after stimulation
with IL-6 (Figure 5F). Inhibition was more pronounced in
some clones in the presence of exogenous Ucn2, suggesting
that endogenous Ucn2 can also stimulate CRHR2 signaling
that leads to efﬁcient pStat3 (Tyr705) down-regulation. The
failure to detect pStat3 (Tyr705) baseline levels is likely due
to the isolation of cancer cells from the tumor microenvi-
ronment as it has been previously reported elsewhere.18
These ﬁndings suggest that CRHR2 signaling may nega-
tively regulate IL-6-mediated Stat3 activation in CRC. Inhi-
bition of pStat3 (Tyr705) was also validated in vivo in
SW620-CRHR2þ resected xenografts treated with Ucn2, as
shown by IHC (Figure 5G).
Corticotropin-Releasing Hormone Receptor
2/Urocortin-2 Signaling Inhibits Interleukin-
6–Mediated Colorectal Cancer Growth
and Oncogenic Epithelial-to-Mesenchymal
Transition in Part Through Regulation of
Stat3-Targeted Genes
In addition to proliferation, inﬂammation in malignant
tumors positively impacts tumor metastasis through regu-
lation of oncogenic EMT.25 Given the CRHR2-mediated Stat3
inhibition, we explored the role of CRHR2/Ucn2 signaling in
CRC proliferative and EMT responses in the presence of IL-
6.
Although IL-6 enhanced the baseline proliferation of
both SW480-CRHR2þ and SW480-EV cells (data not shown),
CRHR2þ growth was signiﬁcantly slower than EV
(Figure 6A). This inhibition was more pronounced in the
presence of exogenous Ucn2 and reversed by Ast2B only in
CRHR2þ cells, suggesting a CRHR2-speciﬁc effect. Prolifer-
ation of EV cells did not statistically signiﬁcantly change in
presence of Ucn2 alone or in combination with Ast2B.
Concomitantly, CRHR2-driven and CRHR2-speciﬁc inhibi-
tion was also observed in IL-6-induced migration
(Figure 6B) and invasion (Figure 6C) of SW620-CRHR2þ
cells in the absence or presence of Ucn2 treatment. Simi-
larly, CRHR2 induction and stimulation with Ucn2
decreased the invasion and migration of the nonmetastatic
cell line DLD1 after pretreatment with IL-6 for 72 hours
(Figure 6D and E, respectively). Surprisingly, Ucn2
increased speciﬁcally the invasion of IL-6 pretreated DLD1-
EV cells but not their migration. These ﬁndings suggest the
involvement of the CRHR2/Ucn2 signaling in the regulation
of IL-6-induced tumor proliferation and EMT onset and/or
progression in CRC.To identify cell cycle– and EMT-relevant gene targets of
CRHR2/Ucn2 signaling in CRC under inﬂammatory condi-
tions at a molecular level, we performed cell cycle– and
EMT-speciﬁc gene arrays using cDNAs from SW480 and
SW620 parental and CRHR2 clones, respectively, treated
with Ucn2 and IL-6. The SW480-CRHR2þ cells had lower
expression of several positive cell cycle regulators involved
in G1 phase and G1/S transition, S phase and DNA replica-
tion, G2 phase and G2/M transition, as well as M phase
progression (Figure 7A, upper panel). Contrarily, induced
expression of genes involved in the regulation of cell cycle
checkpoint and arrest such as cyclin inhibitors as well as
proapoptotic genes Bcl2, Casp3, and TP53 was found in
CRHR2þ cells (Figure 7A, lower panel). Notably, a number of
dysregulated genes in CRHR2þ cells, including members of
the cyclin superfamily and others, are regulated by Stat3.
This suggests that CRHR2/Ucn2 signaling might mediate
inhibitory effects on CRC growth through inhibition of Stat3
under inﬂammatory conditions.
In an EMT-speciﬁc gene array analysis, SW620-CRHR2þ
cells treated with IL-6 and Ucn2 had lower expression of
EMT-promoting genes, including genes involved in cell
migration and motility such as MMPs, CDH2 (N-cadherin),
Vim (Vimentin), TGFb1 and members of the Snail family of
transcription factors (Snail, Twist, ZEB1, and ZEB2)
(Figure 7B, upper panel). In contrast, CRHR2þ cells had
higher levels of critical EMT-suppressor genes including
CDH1 (E-cadherin) and GSK3b (inhibitor of Snail and b-
catenin) (Figure 7B, lower panel). Along with cell cycle
markers, MMPs, Snail, Twist1, CDH1, ZEBs, and other EMT-
regulatory genes with altered expression in CRHR2þ
clones are also downstream targets of Stat3.
The dysregulated expression of some of these gene
products was validated at the protein level by Western blot
analysis (Figure 7C). SW60-CRHR2þ cells had decreased
expression of ZEB as well as vimentin and b-catenin in all
treatments. In contrast, expression of E-cadherin was up-
regulated in CRHR2þ cells. Our molecular ﬁndings overall
suggest that CRHR2/Ucn2 signaling might mediate its
inhibitory effects on IL-6-triggered proliferation and onco-
genic EMT, at least in part, through Stat3 down-regulation.
Low Corticotropin-Releasing Hormone Receptor
2 Expression in Colorectal Cancer Specimens Is
Correlated With Increased Interleukin-6R and
Vimentin Levels, Distant Metastasis, and Poor
Overall Survival
CRHR2, IL-6R, CDH1, and Vim mRNA expression was
assessed by qRT-PCR in all 56 human CRC samples and the
mean ± SEM value was calculated for each gene indepen-
dently of any clinicopathologic parameter. Among the 56
CRC samples tested, 42 had undetectable CRHR2 mRNA
expression (cycle threshold above 40 cycles that was
translated as 0 expression), 3 low [set as CRHR2 levels
< mean ± SEM (0.7215 þ 0.22 ¼ 0.9415)] and 11 samples
high (set as expression > mean ± SEM). Analysis of CRHR2,
E-cadherin, IL-6R, and vimentin mRNA levels in CRC
revealed that samples with low CRHR2 expression (n ¼ 3)
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vimentin (Figure 8B) expression levels than those with high
CRHR2 (n ¼ 11). In contrast, CRC samples with high CRHR2
mRNA levels had signiﬁcant evidence of more E-cadherin
mRNA expression (Figure 8C). Analysis between CRHR2
positive (N ¼ 14) and negative samples (those with unde-
tectable CRHR2 mRNA levels, n ¼ 42) revealed no statisti-
cally signiﬁcant association between the mRNA expression
of CRHR2 and any of the tested genes (data not shown).
Based on the available clinicopathologic data (Table 1),
decreased CRHR2 expression in CRC patients also had evi-
dence of higher occurrence of distant metastasis (Figure 8D)
and of poor prognosis for 5-year survival after treatment
initiation (Figure 8E). A marginally signiﬁcant positive as-
sociation (P ¼ .05) was also observed between CRHR2
expression and normal weight patients as compared with
the overweight patients. No associations were established
between CRHR2 expression and tumor grade (based on
Dukes or TNM classiﬁcation) or tumor differentiation
neither at the mRNA (Table 1) or protein levels (data not
shown). Ucn2 expression in the same patients did not reveal
any associations with any of the studied clinicopathologic
characteristics (Table 1). These ﬁndings suggest that CRHR2
levels might serve as a putative prognostic indicator for
tumor metastatic activity and overall patient outcome.Discussion
This study provides clear evidence for dysregulated
expression of CRHR2 and its speciﬁc agonist Ucn2 in CRC
that impacts critically tumor survival and expansion, at
least, through sustaining inﬂammatory signals and Stat3
activation in the colon. We introduce CRHR2 distribution
and signaling through Ucn2 as a novel negative modulator
of CRC growth in vitro and in vivo as well as a suppressor of
oncogenic EMT that associates with less risk for distant
metastasis and better overall patient survival. Our current
ﬁndings introduce possible links among inﬂammation, the
CRH axis, and CRC, but future studies on an inﬂammation-
associated animal model and CRC patients with IBD his-
tory are necessary to further support a role of the CRH
system in inﬂammation-associated CRC.
It is well-accepted that many CRC cases are linked to the
duration and extension of mucosal inﬂammation. This is
sustained by inﬂammatory cells and the tumor cellsFigure 3. (See previous page) Corticotropin-releasing horm
(CRC) cells inhibits tumor growth and oncogenic epithelial-
induction in SW480 and SW620 inhibits speciﬁcally baseline a
treated with 0.1 mM Ucn2 ± 1 mM astressin-2B (Ast2B) for 72 ho
and CRHR2-speciﬁc baseline and Ucn2-mediated proliferation
.01. (C) SW480-CRHR2þ and SW620-CRHR2þ cells are less e
(empty virus) cells. Cells were treated with 0.1 mM Ucn2 every
CRHR2 showed reduced baseline and Ucn2-mediated migration
were reversed by Ast2B, thus suggesting CRHR2 speciﬁcity. In b
Ucn2 ± 1 mM Ast2B for 48 hours. *P  .05; **P  .01. (F) CRHR2
of NCM460 cells. *P < .05; **P < .01. (G) CRHR2 induction re
migration of SW480 cells. SW620-EV and SW620-CRHR2þ cells
and incubated with or without 15 ng/mL TGFb1 and/or 0.1 mM.
**P  .01.themselves, which modulate the progression of colon
carcinogenesis by producing tumor-supportive cytokines
such as IL-6 or by stimulating synthesis of molecules with
mitogenic effects.26 We show that CRHR2 loss in the ma-
lignant colon promotes and/or sustains proinﬂammatory
signals mediated in part by IL-6 and its receptor IL-6R. This
ﬁnding suggests that CRHR2high CRC tumors may be less
responsive to IL-6 that might be present in high levels
within the tumor microenvironment. This was further vali-
dated in human CRC tissues, where an inverse correlation
between CRHR2high and IL-6Rhigh was established.
Concomitantly, Ucn2 up-regulation found on CRC also
contributed positively in maintaining or promoting high IL-6
levels. Although activation of CRHR1 typically has been
shown to favor proinﬂammatory responses that contribute
to the development of colitis-associated cancer in mouse
models27 and CRHR2 to drive mainly anti-inﬂammatory
responses,28,29 these effects appear to depend on recep-
tor/ligand distribution on colonic mucosa as well as
inﬂammation status (acute or chronic).30,31 Thus, the con-
centration of Ucn available intracellularly or in the micro-
environment might play a critical role in CRHR2-driven pro/
anti-inﬂammatory responses.
In addition, the reported anti-inﬂammatory actions of
Ucn, regulated via CRHR2, have been evidenced only at low
peptide concentrations.32 A rat model of chemically
induced colitis illustrated a proinﬂammatory action for
elevated Ucn2, accompanied by a reduction in CRHR2.5 In
other tissues, such as smooth muscles, Ucn2 is also re-
ported to support topical inﬂammation through induction
of IL-6.33 This suggests that Ucn2-mediated inﬂammation
might be critically involved in CRC and associated with
IBD-related colon cancer. CRHR2 induction in CRC cell
lines resulted in decreased mRNA expression of endoge-
nous Ucn2, while silencing of endogenous Ucn2 in parental
CRC cell lines up-regulated CRHR2 expression. Although it
is likely that endogenous Ucn2 up-regulation might ac-
count for the down-regulation of the respective receptor in
CRC cells or vice versa,5 this is an area worth investigating
in the future.
Most inﬂammation-related autocrine-paracrine events
converging in tumor cells typically result in Stat3 activation,
which mediates a transcriptional response favoring tumor
survival, proliferation, and angiogenesis.24 Functionally, the
most important Stat3 activators are IL-6 and IL-10.one receptor 2 (CRHR2) induction in colorectal cancer
to-mesenchymal transition (EMT) progression. (A) CRHR2
nd urocortin-2 (Ucn2)-mediated cell proliferation. Cells were
urs. (B) NCM460-CRHR2-overexpressing cells have increased
rates compared with parental NCM460 cells. *P < .05; **P <
fﬁcient in forming colonies than corresponding parental EV
2 days for 15 days. (D) SW620- and HCT116-overexpressing
and (E) invasion potential over parental cells. Both responses
oth assays, cells in upper chambers were treated with 0.1 mM
overexpression enhances speciﬁcally the migratory properties
duces Snail/transforming growth factor b1 (TGFb1)-mediated
were transfected with a plasmid vector expressing SnailS6A
Migration was assessed 48 hours after transfection. *P  .05;
Figure 4. Corticotropin-releasing hormone receptor 2 (CRHR2)/urocortin-2 (Ucn2) signaling inhibits speciﬁcally colo-
rectal cancer (CRC) growth and expression of epithelial-to-mesenchymal transition (EMT) markers in vivo. (A) Reduced
tumor volume in mice bearing SW620-CRHR2þ xenografts with or without intratumoral Ucn2 administration. Black arrow
indicates treatment initiation. Statistically signiﬁcant differences in tumor volume were observed at weeks 4, 5, and 6 between
the following groups: EV versus CRHR2þ (P < .003), EV/Ucn2 versus CRHR2þ/Ucn2 (P < .001), and CRHR2þ/Ucn2 versus
CRHR2þ/Ucn2/Ast2B (P < .004). (B) Increased necrosis in resected SW620-CRHR2þ xenograft specimens versus EV (empty
virus) control, as assessed by H&E staining. Scale bar: 2 mm. *P < .05. (C) Increased tumor apoptosis in SW620-CRHR2þ
specimens, as assessed by terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end labeling
assay. Scale bar: 50 mm. *P < .05. (D) Low proliferating cell nuclear antigen (PCNA) expression in SW620-CRHR2þ specimens
indicates reduced tumor proliferation. Scale bar: 50 mm. Black arrow indicates the speciﬁc PCNA staining. (E) Induced
expression of the metastasis-suppressor Raf-1 kinase inhibitory protein (RKIP) and inhibition of the EMT-inducers vimentin, N-
cadherin, and Snail as well as the angiogenesis promoting VEGF in SW620-CRHR2þ specimens derived from Ucn2-treated
mice. Scale bars: 50 mm (scale bars are proportional to the original microscope-derived images).
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Figure 5. Corticotropin-
releasing hormone recep-




ducer and activator of
transcription 3 (Stat3)
activation in colorectal
cancer (CRC). (A) De-
creased IL-6 and IL-1b
mRNAs in CRHR2þ ver-
sus EV (empty virus) CRC
cells. *P < .05; **P < .01.
(B) Inhibition of IL-6R
mRNA expression in
CRHR2þ cells compared
with EV. **P < .01. (C)
Urocortin-2 (Ucn2) inhibi-
tion by small interfering
RNA diminishes IL-6, IL-
1b, and IL-8 mRNA
expression in SW480 cells
(*P < .05) and (D) up-
regulates CRHR2 mRNA
expression in SW620 and
SW480 cells (**P < .01). (E)
CRC specimens express
higher IL-6 and IL-6R
mRNA levels than con-
trols. *P < .05. (F) Inhibition
of IL-6-induced Stat3
(Tyr705) phosphorylation in
CRHR2þ cells after stimu-
lation with 20 ng/mL IL-6
and/or 0.1 mM Ucn2 for
30 minutes, as assessed
by Western blot. Data
shown are from a re-
presentative experiment.
Lanes of bands shown
have been cropped by the
original whole gel images.
(G) Validation of pStat3
(Tyr705) inhibition in
SW620-CRHR2þ resected
tumors from mice treated
with Ucn2. Scale bar: 50
mm (scale bar proportional
to the original microscope-
derived image).







cancer (CRC) growth, in-
vasion, and migration. (A)
CRHR2-dependant inhibi-
tion of IL-6-mediated cell
proliferation of SW480-
CRHR2þ cells. (B, C)
CRHR2 speciﬁc inhibition
of (B) migration and (C) in-
vasion of SW620-CRHR2þ
cells. *P  .05; **P  .01.
(D) CRHR2 induction in-
hibits speciﬁcally the base-
line and Ucn2-mediated
invasion of the non-
metastatic cell line DLD1.




cells. **P < .01. In all assays
CRHR2þ and EV CRC cells
were treated with 20 ng/mL
IL-6 alone or in combination
with 0.1 mM Ucn2 ± 1 mM
Ast2B for 72 hours for pro-
liferation assessment or 48
hours for migration and in-
vasion monitoring. DLD1
cells were pretreated with
20 ng/mL IL-6 for 72 hours
before migration and inva-
sion settings.
November 2015 CRHR2 Inhibition Promotes CRC Metastasis 625Recently, Stat3 has been proposed as a molecular link be-
tween intestinal inﬂammation and tumorigenesis.34 Accu-
mulated evidence indicates that abnormalities in the Janus
kinase (JAK)/Stat pathway are involved in CRC oncogen-
esis,35 with aberrant and persistent Stat3 activation being a
frequent observation in human CRC, often associated with
poor outcome.18,36 We demonstrate for the ﬁrst time that
Stat3 is a downstream target of CRHR2/Ucn2 signaling in
CRC, with CRHR2 induction suppressing IL-6-mediated
Stat3 (Tyr703) phosphorylation in vitro and in vivo. As
such, Stat3 inhibition in CRHR2þ CRC cells might confer
decreased tumor cell proliferation and diminished tumor
growth observed in mice bearing CRHR2þ CRC tumors.Stat3 activation promotes cell cycle G1/S phase tran-
sition in gastric, colon, and squamous cell carcinomas by
stimulating transcription of CCNB1, CDK1, and CCND1
along with repression of the cell cycle inhibitor p21
(CDKN1A).35–42 Consistent with CRHR2-mediated Stat3
inhibition are our ﬁndings from the cell cycle gene arrays
showing CCNB1, CCND1, and CDK1 down-regulation, in-
duction of CDKN1A, and dysregulated expression of genes
involved in G1 phase regulation and G1/S transition,
including ANAPC2, CCNE1, CDKN1B, CUL2, CUL3, and E2F1
in CRHR2þ CRC cells. In addition, Stat3-mediated induc-
tion of survivin (BIRC5)43 and suppression of p53











of cell cycle- and EMT-
related genes. (A) Heat
map representing cell cy-
cle–related gene array data
derived by SW480-EV
and SW480-CRHR2þ cells
treated with 20 ng/mL IL-6
and 0.1 mM Ucn2 for 18






respectively. (B) Heat map
representing EMT-related
gene array data derived
by SW620-EV and SW620-
CRHR2þ cells treated
with 20 ng/mL IL-6 and 0.1
mM Ucn2 for 18 hours.






tively. (C) Validation of EMT
inhibition at protein level in
SW620-CRHR2þ protein
extracts derived after cell
treatment with 20 ng/mL
IL-6 ± 0.1 mM Ucn2. Lanes
of bands shown have been
cropped by the original
whole gel images.
626 Rodriguez et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 6CRHR2 also interferes negatively with Stat3-mediated
apoptosis suppression. The antiproliferative effects of
CRHR2/Ucn2 signaling were further validated in axenograft model with CRHR2þ tumors to show CRHR2þ-










and (B) vimentin mRNA
levels. (C) In contrast, a
positive correlation was
established between E-
cadherin (CDH1) and high
CRHR2 mRNA expression.
Low and high CRHR2 ex-
pressions were set as
detectable CRHR2 mRNA
levels < mean ± standard
error of the mean (SEM) or
> mean ± SEM, respec-
tively, calculated by the to-
tal CRC samples (n ¼ 56).
Among the 56 CRC sam-
ples tested, 3 were found
with low CRHR2 expres-
sion, 11 with high expres-
sion, and the remaining 42
with undetectable expres-
sion. (D) Decreased ex-
pression of CRHR2 in CRC
samples positively corre-
lates with occurrence of
distant metastasis. DM,
distant metastasis (n ¼ 18);
NM, no metastasis (n ¼ 21).
(E) CRC patients with high
tumoral CRHR2 mRNA
expression (n ¼ 11) have an
increased 5-year survival
rate compared with patients
with low CRHR2 expression
(n ¼ 3).
November 2015 CRHR2 Inhibition Promotes CRC Metastasis 627As with the majority of cancers, the progression of CRC to
invasive and metastatic disease may involve localized oc-
currences of oncogenic EMT. Key EMT-inducers in CRC
include Ras, Wnt, PI3K/Akt, and TGFb.45 Recently, the Stat3
pathway was found to arbitrate the EMT process directly in
CRC cells through induction of cell motility, migration and
invasion resulting from increased ZEB1, vimentin, and N-
cadherin expression and suppression of E-cadherin.46 To our
knowledge, this is the ﬁrst report demonstrating negativeeffects of CRHR2/Ucn2 signaling on oncogenic EMT. Previ-
ous studies have reported inhibitory effects of CRHR2/CRH
and CRHR2/Ucn in EMT properties of TGFb-treated breast
cancer and hepatoma cell lines, respectively.47,48 We show
that CRHR2/Ucn2 signaling triggers inhibition of baseline
and IL-6-mediated tumor migration and invasion accompa-
nied by inhibition of mesenchymal markers at the mRNA and
protein levels (in vitro and in vivo) and induction of EMT-
suppressors including E-cadherin.
Figure 9. Schematic representation of the corticotropin-releasing hormone receptor 2 (CRHR2)/urocortin-2 (Ucn2)
targeted pathways and downstream events taking place after ectopic expression of CRHR2 in colorectal cancer (CRC)
cells. (A) Constitutive activation of STAT3 in CRC by interleukin-6 (IL-6)/IL-6R signaling promotes expression of Stat3-targeted
genes that regulate cell cycle and epithelial-to-mesenchymal transition (EMT). (B) CRHR2/Ucn2 signaling inhibits the
expression of tumor-produced proinﬂammatory cytokines (PICs) such as IL-1b or IL-6 either via Ucn2 down-regulation or
through a Ucn2-independent manner. CRHR2/Ucn2 also decreases the expression of IL-6R on the surface of CRC cells, thus
resulting in attenuation of autocrine- or exocrine-mediated IL6R/IL6 signaling, which in turn leads to signiﬁcant inhibition of
Stat3 phosphorylation and its targeted genes. As constitutively active Stat3 is one of the major regulators of cell cycle and
EMT in CRC cells, CRHR2/Ucn2-mediated Stat3 inhibition might facilitate at least in part the decreased proliferative,
migratory, and invasive responses shown in CRHR2þ CRC cells. End, endogenous; Ex, exogenous.
628 Rodriguez et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 6The fact that the dysregulated EMT-related gene signa-
ture in IL-6- treated CRHR2þ cells contained several Stat3-
targeted EMT gene regulators suggests that CRHR2/Ucn2
signaling might mediate its suppressing effects on EMT in
CRC at least via modulation of the IL-6/Stat3 pathway and
its downstream targets. This is supported by previous re-
ports on other cancers showing dependence of EGF-induced
EMT by IL-6R and the JAK2/Stat3 pathway in ovarian can-
cer49 and IL-6-induced head and neck oncogenic EMT via
the JAK/Stat3/Snail pathway.50
We also found decreased VEGF expression in CRHR2þ
xenografts in our in vivo model. VEGF is a prominent
transcriptional target for Stat3,51 thus suggesting that
CRHR2/Ucn2 might partially affect angiogenesis in CRC
through Stat3 suppression. Overall, our ﬁndings point to
Stat3 as one of the underlying molecular targets of CRHR2
signaling that mediates CRHR2/Ucn2 effects on CRC sur-
vival and expansion (Figure 9).
Our ﬁndings demonstrating CRHR2/Ucn2-mediated in-
hibition of CRC migratory potential are partially opposed to
recently reported ﬁndings that show CRHR2/Ucn3 signaling
to favor CRC migration through negative regulation of
cellular adhesion.17 We also failed to detect overexpression
of CRHR2 and Ucn3 in CRC tissues and many CRC cell lines,
or to establish positive correlations with high-grade andpoorly differentiated tumors as observed by Ducarouge
et al.17 These differing results can be also explained by the
larger number of tissue samples (both CRC and normal) we
used in our study. In addition, the in vivo validation of our
in vitro ﬁndings strongly supports our proposed role of
CRHR2/Ucn2 signaling on negative regulation of CRC
growth and EMT.
Finally, we demonstrated inverse correlations among
CRHR2, vimentin, and IL-6R expression as well as positive
CRHR2 associations with E-cadherin in clinical CRC samples.
CRHR2 underexpression or loss in CRC was further associ-
ated with increased incidence of distant metastases and
poor survival of CRC patients, suggesting a potential clinical
relevance of CRHR2 decrease/loss on CRC outcome.
Given the high incidence of CRC cases worldwide and
increased lethality due to distant metastases, identifying
novel regulatory pathways involved in CRC growth and
metastasis is paramount. We present novel ﬁndings on the
role of the CRH system in CRC pathophysiology and molec-
ular evidence to link CRHR2/Ucn2 signaling with CRC
growth and aggressiveness through modulation of inﬂam-
matory responses in the colon. We propose that evaluation of
CRHR2/Ucn2 expression in CRC may beneﬁt early diagnosis
of aggressive tumors and serve as a novel therapeutic target
for prevention and treatment of advanced stages of CRC.
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